Three-month functional outcomes following endovascular thrombectomy during the first wave of the COVID-19 pandemic: a Canadian single-center cohort study.


Journal

Journal of neurointerventional surgery
ISSN: 1759-8486
Titre abrégé: J Neurointerv Surg
Pays: England
ID NLM: 101517079

Informations de publication

Date de publication:
Mar 2022
Historique:
received: 14 04 2021
accepted: 23 04 2021
pubmed: 4 6 2021
medline: 19 2 2022
entrez: 3 6 2021
Statut: ppublish

Résumé

The COVID-19 pandemic has disrupted acute stroke care logistics, including delays in hyperacute management and decreased monitoring following endovascular therapy (EVT). We aimed to assess the impact of the pandemic on 90-day functional outcome among patients treated with EVT. This is an observational cohort study including all patients evaluated for an acute stroke between March 30, 2020 and September 30, 2020 (pandemic cohort) and 2019 (reference cohort) in a high-volume Canadian academic stroke center. We collected baseline characteristics, acute reperfusion treatment and management metrics. For EVT-treated patients, we assessed the modified Rankin score (mRS) at 90 days. We evaluated the impact of the pandemic on a 90-day favourable functional status (defined as mRS 0-2) and death using multivariable logistic regressions. Among 383 and 339 patients included in the pandemic and reference cohorts, baseline characteristics were similar. Delays from symptom onset to evaluation and in-house treatment were longer during the early first wave, but returned to reference values in the subsequent months. Among the 127 and 136 EVT-treated patients in each respective cohort, favourable 90-day outcome occurred in 53/99 (53%) vs 52/109 (48%, p=0.40), whereas 22/99 (22%) and 28/109 (26%, p=0.56) patients died. In multivariable regressions, the pandemic period was not associated with 90-day favourable functional status (aOR 1.27, 95% CI 0.60 to 2.56) or death (aOR 0.74, 95% CI 0.33 to 1.63). In this single-center cohort study conducted in a Canadian pandemic epicenter, the first 6 months of the COVID-19 pandemic did not impact 90-day functional outcomes or death among EVT-treated patients.

Sections du résumé

BACKGROUND BACKGROUND
The COVID-19 pandemic has disrupted acute stroke care logistics, including delays in hyperacute management and decreased monitoring following endovascular therapy (EVT). We aimed to assess the impact of the pandemic on 90-day functional outcome among patients treated with EVT.
METHODS METHODS
This is an observational cohort study including all patients evaluated for an acute stroke between March 30, 2020 and September 30, 2020 (pandemic cohort) and 2019 (reference cohort) in a high-volume Canadian academic stroke center. We collected baseline characteristics, acute reperfusion treatment and management metrics. For EVT-treated patients, we assessed the modified Rankin score (mRS) at 90 days. We evaluated the impact of the pandemic on a 90-day favourable functional status (defined as mRS 0-2) and death using multivariable logistic regressions.
RESULTS RESULTS
Among 383 and 339 patients included in the pandemic and reference cohorts, baseline characteristics were similar. Delays from symptom onset to evaluation and in-house treatment were longer during the early first wave, but returned to reference values in the subsequent months. Among the 127 and 136 EVT-treated patients in each respective cohort, favourable 90-day outcome occurred in 53/99 (53%) vs 52/109 (48%, p=0.40), whereas 22/99 (22%) and 28/109 (26%, p=0.56) patients died. In multivariable regressions, the pandemic period was not associated with 90-day favourable functional status (aOR 1.27, 95% CI 0.60 to 2.56) or death (aOR 0.74, 95% CI 0.33 to 1.63).
CONCLUSION CONCLUSIONS
In this single-center cohort study conducted in a Canadian pandemic epicenter, the first 6 months of the COVID-19 pandemic did not impact 90-day functional outcomes or death among EVT-treated patients.

Identifiants

pubmed: 34078648
pii: neurintsurg-2021-017664
doi: 10.1136/neurintsurg-2021-017664
doi:

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

274-279

Informations de copyright

© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Joel Neves Briard (J)

Neurosciences, Université de Montréal, Montreal, Quebec, Canada.
Neurology, CHUM, Montreal, Quebec, Canada.

Gabrielle Dufort (G)

Neurosciences, Université de Montréal, Montreal, Quebec, Canada.
Neurology, CHUM, Montreal, Quebec, Canada.

Grégory Jacquin (G)

Neurosciences, Université de Montréal, Montreal, Quebec, Canada.
Neurology, CHUM, Montreal, Quebec, Canada.

Walid Alesefir (W)

Neurosciences, Université de Montréal, Montreal, Quebec, Canada.
Neurology, CHUM, Montreal, Quebec, Canada.

Olena Bereznyakova (O)

Neurosciences, Université de Montréal, Montreal, Quebec, Canada.
Neurology, CHUM, Montreal, Quebec, Canada.

William Boisseau (W)

Radiology, Université de Montréal, Montreal, Quebec, Canada.
Radiology, CHUM, Montreal, Quebec, Canada.

Nicole Daneault (N)

Neurosciences, Université de Montréal, Montreal, Quebec, Canada.
Neurology, CHUM, Montreal, Quebec, Canada.

Yan Deschaintre (Y)

Neurosciences, Université de Montréal, Montreal, Quebec, Canada.
Neurology, CHUM, Montreal, Quebec, Canada.

Jose Danilo Bengzon Diestro (JDB)

Radiology, Université de Montréal, Montreal, Quebec, Canada.
Radiology, CHUM, Montreal, Quebec, Canada.

Célina Ducroux (C)

Neurosciences, Université de Montréal, Montreal, Quebec, Canada.
Neurology, CHUM, Montreal, Quebec, Canada.

Johanna Eneling (J)

Radiology, Université de Montréal, Montreal, Quebec, Canada.
Radiology, CHUM, Montreal, Quebec, Canada.

Laura Gioia (L)

Neurosciences, Université de Montréal, Montreal, Quebec, Canada.
Neurology, CHUM, Montreal, Quebec, Canada.

Daniela E Iancu (DE)

Radiology, Université de Montréal, Montreal, Quebec, Canada.
Radiology, CHUM, Montreal, Quebec, Canada.

Céline Odier (C)

Neurosciences, Université de Montréal, Montreal, Quebec, Canada.
Neurology, CHUM, Montreal, Quebec, Canada.

Jean Raymond (J)

Radiology, Université de Montréal, Montreal, Quebec, Canada.
Radiology, CHUM, Montreal, Quebec, Canada.

Daniel Roy (D)

Radiology, Université de Montréal, Montreal, Quebec, Canada.
Radiology, CHUM, Montreal, Quebec, Canada.

Christian Stapf (C)

Neurosciences, Université de Montréal, Montreal, Quebec, Canada.
Neurology, CHUM, Montreal, Quebec, Canada.

Alain Weill (A)

Radiology, Université de Montréal, Montreal, Quebec, Canada.
Radiology, CHUM, Montreal, Quebec, Canada.

Alexandre Y Poppe (AY)

Neurosciences, Université de Montréal, Montreal, Quebec, Canada alexandre.poppe.med@ssss.gouv.qc.ca.
Neurology, CHUM, Montreal, Quebec, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH